Several studies demonstrated that
lncRNA differentiation antagonizing
non-protein coding RNA (
lncRNA DANCR) expression might have the potential capacity to predict the
cancer prognosis; however, definite conclusion has not been obtained. The aim of this meta-analysis was to evaluate the prognostic value of
lncRNA DANCR expression in
cancers. PubMed, Web of Science, Scopus, and Embase were comprehensively searched for relevant studies. Studies meeting all inclusion standards were included into this meta-analysis. The analysis of overall survival (OS), disease-free survival (DFS), or clinicopathological features was conducted. Total 11 studies containing 1154
cancer patients were analyzed in this meta-analysis. The results showed, compared with low
lncRNA DANCR expression, high
lncRNA DANCR expression was significantly associated with shorter OS (hazard ratio [HR] = 1.85; 95% CI = 1.52-2.26; P<0.01) and DFS (HR = 1.82; 95% CI = 1.43-2.32; P<0.01) in
cancers. Besides, high
lncRNA DANCR expression predicted deeper
tumor invasion (P<0.01), earlier
lymph node metastasis (P<0.01), earlier distant
metastasis (P<0.01), and more advanced clinical stage (P<0.01) compared with low
lncRNA DANCR expression in
cancer populations. High
lncRNA DANCR expression was associated with worse prognosis compared with low
lncRNA DANCR expression in
cancers.
LncRNA DANCR expression could serve as a prognostic factor of human
cancers.